FLASH SPRING SALE: 50% Off Premium Subscription >> FLASH SPRING SALE: 50% Off Premium >>
$1.24
-0.0200 (-1.59%)
At Close: May 01, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $1.23 $1.93 Wednesday, 1st May 2024 AKBA stock ended at $1.24. This is 1.59% less than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 4.84% from a day low at $1.24 to a day high of $1.30.
90 days $1.23 $2.47
52 weeks $0.780 $2.47

Historical Akebia Therapeutics prices

Date Open High Low Close Volume
Sep 26, 2022 $0.320 $0.330 $0.303 $0.308 1 119 826
Sep 23, 2022 $0.317 $0.331 $0.301 $0.320 2 039 050
Sep 22, 2022 $0.360 $0.360 $0.322 $0.332 1 852 307
Sep 21, 2022 $0.357 $0.369 $0.351 $0.354 815 621
Sep 20, 2022 $0.355 $0.371 $0.353 $0.365 1 329 765
Sep 19, 2022 $0.386 $0.386 $0.355 $0.365 2 008 743
Sep 16, 2022 $0.371 $0.390 $0.352 $0.386 1 557 411
Sep 15, 2022 $0.390 $0.390 $0.366 $0.370 1 327 864
Sep 14, 2022 $0.392 $0.398 $0.373 $0.381 1 247 310
Sep 13, 2022 $0.410 $0.418 $0.387 $0.388 2 415 198
Sep 12, 2022 $0.440 $0.440 $0.413 $0.423 1 780 535
Sep 09, 2022 $0.421 $0.445 $0.421 $0.435 1 667 356
Sep 08, 2022 $0.407 $0.450 $0.401 $0.430 3 897 502
Sep 07, 2022 $0.383 $0.410 $0.381 $0.400 3 383 427
Sep 06, 2022 $0.370 $0.387 $0.365 $0.382 2 269 786
Sep 02, 2022 $0.376 $0.388 $0.368 $0.380 1 208 859
Sep 01, 2022 $0.357 $0.375 $0.352 $0.370 1 284 249
Aug 31, 2022 $0.363 $0.377 $0.360 $0.364 1 203 015
Aug 30, 2022 $0.376 $0.377 $0.352 $0.355 1 595 615
Aug 29, 2022 $0.360 $0.379 $0.360 $0.367 1 706 095
Aug 26, 2022 $0.397 $0.400 $0.369 $0.376 2 228 642
Aug 25, 2022 $0.388 $0.410 $0.388 $0.400 2 042 169
Aug 24, 2022 $0.370 $0.400 $0.364 $0.390 2 657 419
Aug 23, 2022 $0.366 $0.380 $0.365 $0.370 1 314 840
Aug 22, 2022 $0.385 $0.389 $0.352 $0.370 3 220 298
Click to get the best stock tips daily for free!

About Akebia Therapeutics

Akebia Therapeutics Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra... AKBA Profile

Golden Star

Ticker Date Change Price
HRB Apr 29 1.00% $47.23
LYG Apr 29 0.391% $2.56
ORA Apr 29 1.95% $64.48
ETSY Apr 26 3.43% $67.43
DHT Apr 24 0.98% $11.28
LPLA Apr 19 1.10% $262.59
MLI Apr 19 7.29% $52.28
PFLT Apr 18 1.33% $11.25
DOOR Apr 18 0.94% $131.39
OCSL Apr 17 0.360% $19.43
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT